Across TCGA pan-cancer cohorts, MRTFA mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MRTFA data layer compared with 17 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MRTFA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MRTFA expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where MRTFA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.802	0.529	.004	20	view →
LSCC	DFS	Quartile	II,III,IV	0.452	0.893	.003	20	view →
LUAD	DFS	Median	All	0.721	0.535	.025	10	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: MRTFA tumor-vs-normal RNA expression · all MRTFA data types